Penis Enlargement: What Actually Works

The global erect mean is 13.12 cm (5.2 in), and two thirds of all men fall within 11.5–14.8 cm. If you have not measured properly yet, do that before you buy anything — the calculator takes a minute, and partner-preference studies will probably recalibrate your worry. With that said: here is every method, graded.

Scam

No randomized trial has ever shown a pill or cream increasing penis size. Not one. These products are unregulated blends sold against a Photoshop comparison and a countdown timer. The active ingredient is your insecurity. If a pill could do this, Pfizer would sell it by the pallet.

Scam

Zero supporting evidence — and a real injury pattern. Urologists report burst capillaries, thrombosis, and curvature (acquired Peyronie's-like changes) from aggressive squeezing routines. You are risking the one thing every method on this list is trying to protect: function.

Real, but temporary

Real but fleeting: negative pressure pulls blood and interstitial fluid in, producing a visibly larger erection for minutes to a couple of hours. Nothing structural changes. Legitimate as an erection aid (that is their actual medical use), useless as an enlargement strategy.

Real, with caveats

The only non-surgical method with controlled data. In the pilot trial by Gontero et al. (BJU International, 2009), daily extender use for months produced roughly 1.5–2.3 cm of stretched/flaccid gain; a 2011 BJU review (Oderda & Gontero) concluded traction should be the first-line option for men seeking length. The catch is the protocol: hours of daily wear, for months, for a modest result. It works the way braces work — slow, mechanical, unsexy, real.

Real, but temporary

The strongest evidence in the entire enhancement field. A multicenter randomized trial (Yang et al., J Sex Med 2020, 18-month follow-up) and a 2023 meta-analysis (Kusumaputra et al., Annals of Medicine & Surgery) put average erect girth gains at roughly 2–2.5 cm. The product is the same hyaluronic acid used in facial aesthetics, it is reversible with hyaluronidase, and the effect resorbs over 12–18 months — so it is a subscription, not a purchase.

The honest fine print from the complication literature (Quan et al., Asian J Androl 2021; Pignanelli et al., Transl Androl Urol 2025): nodules, asymmetry and filler migration happen and occasionally need dissolving or surgical cleanup. Choose a urologist who does this weekly, not a med-spa with a coupon. Note: fillers add girth, not length — nothing here moves you along the length axis of the chart.

Weak evidence

Your own fat, liposuctioned and injected for girth. Sounds elegant; behaves badly. Reabsorption is unpredictable (a third to most of the volume can vanish within a year), and uneven resorption leaves lumps and asymmetry that are harder to fix than the original concern. Most reviews file it under "not recommended as a first choice."

Weak evidence

Cutting the suspensory ligament drops the flaccid hang lower — it is a locker-room procedure, not a bedroom one. Erect length barely changes, because the ligament anchors angle, not size. Reported satisfaction is lukewarm, and scar retraction can undo the gain or worse. For a surgery, the return is remarkably small.

Weak evidence

The only implant with regulatory clearance (FDA-cleared, cosmetic flaccid enhancement). The 2024 multi-institutional data (Siegal et al.; Salkowski et al., Ther Adv Urol) show satisfied patients — and non-trivial complication and revision rates: infection, seroma, migration, removal. This is a real operation with real stakes, for a result that mainly shows when flaccid. If you are even considering it, read the complication series first and only talk to high-volume urologists.

Not on the market, so nobody advertises it: losing the pubic fat pad. Suprapubic fat buries the base of the shaft; dropping into the 10–12% body-fat range visibly reveals length that was always yours. Combine that with measuring bone-pressed and most men gain more "size" from a deficit than from any syringe — free, permanent, and good for everything else too. That is the whole thesis of our free 80/20 Report.

• Veale D, et al. BJU Int. 2015 — the global baseline used across this site (n = 15,521).
• Gontero P, et al. BJU Int. 2009 — penile extender pilot trial.
• Oderda M, Gontero P. BJU Int. 2011 — non-invasive lengthening review.
• Yang DY, et al. J Sex Med. 2020 — HA vs PLA filler randomized trial (18-month follow-up).
• Kusumaputra A, et al. Ann Med Surg. 2023 — systematic review & meta-analysis, HA/PLA fillers.
• Quan Y, et al. Asian J Androl. 2021 — filler complications and management.
• Salkowski M, et al. Ther Adv Urol. 2024; Siegal AR, et al. Ther Adv Urol. 2024 — Penuma outcomes and safety series.
• Pignanelli M, et al. Transl Androl Urol. 2025 — complications of enhancement procedures.